A role for RIPK1/RIPK3 activation has been proposed as a beneficial proximal target in the initiation of tumor immunity, so that maximizing the immunogenicity of dying cells within the tumor microenvironment through the specific activation of necroptosis may represent an advantageous treatment approach [127]. This evidence concerns the gene RIPK3 and neoplasm.